Comparative Efficacy of Ruksha Purva and Sneha Purva Siravedhana Combined with Nitya Virechana in the Management of Yakrutodara (Non-Alcoholic Fatty Liver Disease): A Randomized Clinical Trial

Background:Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disorder associated with obesity, insulin resistance, and metabolic syndrome. In Ayurveda, its clinical manifestations may be correlated with Yakrutodara, characterized by Mandagni, Kapha-Pitta Dushti, Meda Dhatu Vriddhi, and Srotorodha. Ayurvedic interventions such as Siravedhana, Udvartana, and Nitya Virechana are traditionally employed to address these pathological changes. Objective:To evaluate and compare the efficacy of Ruksha Purva Siravedhana and Sneha Purva Siravedhana, each combined with Udvartana and Nitya Virechana, in the management of Yakrutodara (NAFLD). Materials and Methods: An open-label, randomized comparative clinical trial was conducted in 30 patients diagnosed with Yakrutodara (NAFLD). Participants were randomly allocated into two groups of 15 each using a computergenerated randomization sequence. Group A received Ruksha Purva Siravedhana along with Udvartana and Nitya Virechana, whereas Group B received Sneha Purva Siravedhana, preceded by Sadhyo Snehapana with Murchhita Go Ghrita, along with the same treatment regimen. Subjective parameters, including Ajirna, Aruchi, Adhmana, Chhardi, Atilalasrava, and Vibandha, and objective parameters, including serum SGPT, SGOT, and Fatty Liver Index (FLI), were assessed before and after treatment. Statistical analysis was performed using IBM SPSS Statistics. Results: All 30 participants completed the study without treatment-related adverse events. Both groups showed significant improvement in major subjective symptoms and a significant reduction in FLI. Group B demonstrated significantly greater improvement in Vibandha compared with Group A. Group A showed no significant changes in SGPT or SGOT, whereas Group B demonstrated a statistically significant increase in both liver enzyme levels after treatment. Conclusion: Both treatment protocols improved clinical manifestations and reduced hepatic steatosis. Sneha Purva Siravedhana was more effective for Vibandha, while Ruksha Purva Siravedhana maintained stable liver enzyme levels. Further studies with larger samples are warranted.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Delivery Technology
Published
2026-11-17
DOI
https://doi.org/10.25258/ijddt.16.80s.126
Primary Topic
Traditional Chinese Medicine Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative Efficacy of Ruksha Purva and Sneha Purva Siravedhana Combined with Nitya Virechana in the Management of Yakrutodara (Non-Alcoholic Fatty Liver Disease): A Randomized Clinical Trial

Sangeeta Hemant Toshikhane, Riva A. Joshi
3 links
International Journal of Drug Delivery Technology
Traditional Chinese Medicine Studies
article

Comparative Efficacy of Ruksha Purva and Sneha Purva Siravedhana Combined with Nitya Virechana in the Management of Yakrutodara (Non-Alcoholic Fatty Liver Disease): A Randomized Clinical Trial

Sangeeta Hemant Toshikhane, Riva A. Joshi
article en

Abstract

Background:Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disorder associated with obesity, insulin resistance, and metabolic syndrome. In Ayurveda, its clinical manifestations may be correlated with Yakrutodara, characterized by Mandagni, Kapha-Pitta Dushti, Meda Dhatu Vriddhi, and Srotorodha. Ayurvedic interventions such as Siravedhana, Udvartana, and Nitya Virechana are traditionally employed to address these pathological changes. Objective:To evaluate and compare the efficacy of Ruksha Purva Siravedhana and Sneha Purva Siravedhana, each combined with Udvartana and Nitya Virechana, in the management of Yakrutodara (NAFLD). Materials and Methods: An open-label, randomized comparative clinical trial was conducted in 30 patients diagnosed with Yakrutodara (NAFLD). Participants were randomly allocated into two groups of 15 each using a computergenerated randomization sequence. Group A received Ruksha Purva Siravedhana along with Udvartana and Nitya Virechana, whereas Group B received Sneha Purva Siravedhana, preceded by Sadhyo Snehapana with Murchhita Go Ghrita, along with the same treatment regimen. Subjective parameters, including Ajirna, Aruchi, Adhmana, Chhardi, Atilalasrava, and Vibandha, and objective parameters, including serum SGPT, SGOT, and Fatty Liver Index (FLI), were assessed before and after treatment. Statistical analysis was performed using IBM SPSS Statistics. Results: All 30 participants completed the study without treatment-related adverse events. Both groups showed significant improvement in major subjective symptoms and a significant reduction in FLI. Group B demonstrated significantly greater improvement in Vibandha compared with Group A. Group A showed no significant changes in SGPT or SGOT, whereas Group B demonstrated a statistically significant increase in both liver enzyme levels after treatment. Conclusion: Both treatment protocols improved clinical manifestations and reduced hepatic steatosis. Sneha Purva Siravedhana was more effective for Vibandha, while Ruksha Purva Siravedhana maintained stable liver enzyme levels. Further studies with larger samples are warranted.

International Journal of Drug Delivery TechnologyVol. 16(80s)
National Institute of Ayurveda (IN), Parul University (IN), Parul University (IN)
Good health and well-being
Traditional Chinese Medicine Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon